SIN-CHN
SCIENTIFIC PRESS PTE.LTD.

Molecular & Cellular Biomechanics 2024, 21, 130.
https://doi.org/10.62617/mcb.v21.130

Article

Navigating the biomechanical landscape: Enhanced methods for drug analysis

Shanghui Sun

College of Pharmacy, Heilongjiang University of Chinese Medicine, Harbin 150006, China; shanghuis0201@gmail.com

CITATION

Sun S. Navigating the biomechanical landscape: Enhanced methods for drug analysis. Molecular & Cellular Biomechanics. 2024; 21: 130. https://doi.org/10.62617/mcb.v21.130

ARTICLE INFO

Received: 6 May 2024
Accepted: 7 June 2024
Available online: 23 July 2024

Abstract: In drug analysis and detection, chemiluminescence is a standard technical method based on the idea that the concentration of observed substances in the chemical detection system and the chemical luminescence intensity establish a linear quantitative relationship under certain conditions. Bio-mechanical landscape (BML), which uses bioengineered systems to simulate essential elements of the human tumour microenvironment, is already enhancing cancer biology and aiding clinical translation. The majority of illicit substances have dangerous cardiovascular side effects that might range from an irregular heartbeat to a heart attack. Cardiovascular disease, including blocked veins and bacterial infections of the blood arteries and heart valves, may also result from injecting illicit narcotics. The challenging characteristics of such a cardiovascular disease using drug analysis are heart failure, low blood pressure and headaches. Hence, in this research, drug analysis has improved wearable body sensor network-enabled artificial neural network (WBSN-ANN) technologies for cardiovascular disease. Medicine and drug development because they provide information on patient status in the clinical context and vital information on pharmacodynamics activity, effectiveness, and safety throughout the research process. The process results in a research-intensive organization finding a novel chemical or biological compound and developing it into a medicine that patients can legally utilize for drug discovery and development.

Keywords: drug analysis; cardiovascular disease; biomechanical landscape; wearable body sensor network; artificial neural network

1. Overview

1.1. Background

Recently, it demonstrated that drug analysis can be extracted and analyzed in a pulsatillated manner at sub-nomogram to pictogram levels while maintaining acceptable stability and repeatability. Numerous analyte polarity ranges were examined [1]. The use of one drug or a combination of substances to incapacitate a victim is known as a drug-facilitated crime (DFC). Historically, to prove that drugs were administered, biological samples from victims have been collected and analyzed [2]. Until now, extremely good findings in detecting drug compounds in bodily fluids have been produced and documented in the literature using potentiometric sensors. Potentiometry-based sensors have been created to identify drug molecules in various biological fluids, including blood serum and urine, and discuss their functional characteristics in these contexts [3]. Even though it is still challenging to provide all patients with equal access to well-researched treatments, there are still significant gaps in the pharmacological arsenal for common types of cardiovascular disease, such as peripheral and coronary arterial disease, heart failure,

hypertension, and arrhythmia [4]. Despite these significant benefits, resolving the socio-political, technological, cultural, and economic obstacles to precision medicine implementation is necessary [5].

1.2. Background of the existing studies

A qualified researcher conducted in-person interviews with pharmacists at randomly chosen community pharmacies using a standardized questionnaire. The survey gathered demographic data and details on attitudes and behaviour related to CVD medication treatment [6]. Genetic variation may help better understand the health hazards associated with individual exposure to air pollutants. It's becoming increasingly apparent that different people are affected by air pollution differently and that certain groups are more susceptible to its adverse effects than others [7]. Thus, a comprehensive comprehension of iron metabolism processes and ferroptosis in cardiomyocytes may result in enhanced disease treatment. This Review provides an overview of the connection between ferroptosis and the metabolic and molecular pathways of iron signaling in cardiovascular disease [8,9]. Whether a person had prior cardiovascular disease or not, pharmacologic blood pressure reduction successfully reduced severe cardiovascular disease events, and this impact was unaffected by the person's baseline blood pressure level [10].

There is decreased interest in the effectiveness of mass drug administration (MDA) to expedite elimination due to the introduction of well-tolerated antimalarial [11]. A strategy to allow early and maybe customized prevention has been suggested: genetic characterization. It has long been known that rare Mendelian pathogenic mutations leading to cardiometabolic disorders raise the risk of illness in certain families [12]. They are often used for nefarious activities, including drug-facilitated crimes, suicide, and kidnapping. Their examination of food, biological, and environmental matrices is crucial to ensuring food safety, supporting clinical research, and conducting ecological investigations [13,14]. There are many ways in which obesity raises the risk of cardiovascular disease. To achieve the maximum possible decrease in their risk of cardiovascular disease, obese people will likely need therapy that addresses both obesity and disorders linked with obesity [15].

1.3. Problem definition

However, conventional approaches frequently have difficulty in inaccurate information, which can cause heart failure, low blood pressure and headaches, which is why novel solutions are required for financial.

The challenging characteristic of such a cardiovascular disease using drug analysis is that heart failure, low blood pressure and headaches are resolved by using WBSN-ANN.

1.4. The main contribution of the paper

- To design and develop a system to discuss cardiovascular disease through drug analysis for patients.
- Optimizing the block structure developed based on inaccurate information can lead to heart failure, low blood pressure and headaches for bio mechanism for

drug analysis.

- The wearable body sensor network-enabled artificial neural network (WBSN-ANN) has been used to design, and verify the bio mechanism for cardiovascular disease patients through drug analysis.
- The experiment's outcome was confirmed by using WBSN-ANN counterparts for performance analysis, recall analysis, precision analysis, efficiency analysis, and accuracy analysis.

Significant advancements:

- One possibility is to look at the role of light responses in relation to certain biomarkers linked to cardiovascular disease.
- Develop a perfect portable device that rely on chemiluminescence so that risk assessments may be carried out quickly.
- It would be a good idea to apply the BML principles to studies of the cardiovascular system by simulating its parts.
- The usage of WBSN-ANN for the aim of real-time monitoring of cardiovascular parameters and the construction of customized risk profiles upon the basis of data obtained from wearable sensors. Furthermore, prediction models should be used to execute early intervention strategies.

Key findings and significant advancements:

- There is no better tool for risk assessment than the LVQ, thanks to its robustness and interpretability.
- Both patient care and treatment outcomes may benefit from personalized medicine.
- Crucial information on pharmacodynamics, effectiveness, and safety is supplied by WBSN-ANN.
- Medications may be developed by organizations that invest substantially in research, which leads to the discovery of novel compounds.

1.5. Organization of the paper

The section 2 of the article will address related studies and their findings. Section 3 delves into the article's analysis and presents the factor models used for WBSN-ANN detection. In section 4, we compared our findings and forum to those of an established technique. The study concludes with section 5, which, based on the analysis given in section 4, considers the following research scope.

2. Survey

Al-Sanea and Gamal [16] introduced the first set of medications examined using High-Performance Liquid Chromatography in conjunction with a refractive index detector (HPLC-RI) was examined. As a valuable reference for all analysts in quality control units, the list of all medicines analyzed and the chromatographic conditions for every technique were shown. The last way to get a complete picture of the RI detector's environmentally beneficial qualities is to score each HPLC-RI technique covered here using a greenness rating tool. Many HPLC-RI techniques have been used for drug analysis in pharmaceuticals and animal plasma. With stressful degradations in most of these techniques, just one medication was found.

Dijkshoorn et al. [17] proposed that patients with rheumatoid arthritis (RA) have a 1.5-fold increased risk of cardiovascular diseases (CVD) as compared to the general population. Systemic inflammation has a role in enhanced atherogenesis, which partly contributes to this risk. Nearly 50% of the risk of CVD is also associated with an increased prevalence of "traditional" cardiovascular risk factors, such as dyslipidemia and hypertension. In summary, RA patients continue to have a higher chance of acquiring CVD today. Modern anti-inflammatory medications reduce this risk to some extent. Still, for RA patients' risk of CVD to approach that of the general population, they must be required to undergo obligatory screening for CV risk factors.

Terentes-Printzios et al. [18] discussed that patients with cardiovascular disease (CVD) often have sexual dysfunction, particularly erectile dysfunction (ED) in males. Endothelial dysfunction, inflammation, and low plasma testosterone levels are examples of the pathophysiological connections and risk factors shared by ED and CVD. The impact of pharmacological ED therapy on CVD risk is inconclusive, pointing to a complicated interplay between ED and CVD medication. In this Review, we address how sexual function should be included in the patient history that doctors taking care of patients with CVD should collect, not only as a component of the diagnostic process but also as a way to seek concrete and essential improvements in cardiovascular and quality of life outcomes.

Zhu et al. [19] explained the importance of exploring the significance of macrophage-associated networks in the prognosis and therapy of prostate cancer (PCa) since it is an immune-sensitive tumour. Using a consensus clustering approach, the effect of macrophages on PCa was assessed. Macrophage-related marker genes (MRMGs) were discovered by a thorough study of single-cell sequencing data from GSE141445. Research shows the use of MRMGPS in prognosticating PCa patients. Furthermore, it offers a fresh viewpoint and theoretical underpinning for immunological studies and PCa treatment recommendations.

Liu et al. [20] analyzed that drug misuse puts human life, health, and social security at grave risk. The global drug control situation is dire right now, and more resources are needed to find a solution and stop the drug's spread. Reliable and effective drug detection equipment is crucial to the fight against drugs. After conventional and synthetic drugs, it is now a third-generation drug that is widely used worldwide. Its effects are comparable to or more potent than those of regulated substances in terms of excitatory, hallucinogenic, narcotic, and other effects. The future space is analyzed using artificial intelligence machine learning-based drug detection technology.

Grinspoon et al. [21] reviewed that individuals infected with the human immunodeficiency virus (HIV) have an elevated risk of cardiovascular disease; hence, information on primary preventive methods is required in this group. The main outcome was a significant adverse cardiovascular event, which included cardiovascular mortality, myocardial infarction, hospitalization for unstable angina, stroke, transient ischemic attack, peripheral arterial ischemia, revascularization, or death from an unexplained cause. Compared to those who received a placebo, HIV-positive participants who took pitavastatin had a decreased risk of a significant adverse cardiovascular event over a median.

Isola et al. [22] introduced the involvement of microRNAs (miRNAs) in several epigenetic processes associated with increased oxidative stress which has been shown by recent growing research. Regarding gingival crevicular fluid (GCF) miRNA expression linked to CVD risk, the current research sought to determine periodontitis's effect and identify potential confounders that may have impacted this relationship. Study findings indicated that compared to healthy controls and CVD participants, the group with periodontitis and the group with periodontitis CVD expressed more GCF miRNAs. Furthermore, it was shown that GCF miRNAs linked to the risk of CVD were significantly predicted by the degree of periodontitis (PISA).

Smith and Nguyen [23] study the application of cutting-edge spectroscopic techniques for drug analysis in biomechanical systems. These techniques include Raman spectroscopy and Fourier-transform infrared spectroscopy (FTIR), among others. Obtaining profound molecular insights and detecting medication interactions at the cellular level are both possible outcomes of their study, which demonstrates that these approaches are also valuable. The issue of merging these methods with computer models is explored in depth in this article, with the goal of further enhancing the accuracy of pharmaceutical administration systems.

Patel and Li [24] provide a comprehensive review of the microfluidic devices that have been created for using high-throughput drug screening methodology. The study highlights miniaturization and automation in microfluidic devices as crucial elements that allow speedy and efficient testing of pharmacological compounds. These qualities are identified as particularly important in the research. They discuss the many designs and materials that may be used for microfluidic devices, as well as the ways in which these variables influence the scalability and reproducibility of drug analysis.

This study from 2024 examines how artificial intelligence and machine learning are used in computer modelling for the sake of medication development [25]. In doing so, they draw attention to recent advancements in molecular docking, virtual screening, and predictive modelling. Additionally, the research examines instances of how artificial intelligence and machine learning have been used to discover novel pharmaceutical candidates. This demonstrates the significance of these technologies in terms of accelerating the process of drug development.

Although nanofibers, liposomes, and nanoparticles are all mentioned in Martinez and Kim's [26] discussion of nanotechnology in drug delivery systems, they are not given any particular attention. The researchers are looking at how these nanomaterials may boost the bioavailability of medications and the targeted distribution of those medications in order to improve treatment outcomes while simultaneously reducing undesirable effects. Within the realm of nanomedicine, this page provides a comprehensive summary of all the ongoing and forthcoming clinical trials and research subjects.

New passive finite element (FE) models of the spine that make use of force-displacement control were developed by the authors of the study that was carried out by Abbasi-Ghiri and colleagues [27]. Due to the fact that these models simulate both healthy and pathological states, it is possible to make comparisons with both passive and advanced musculoskeletal models. This research offers fresh insights into

biomechanical behavior and the potential applications of this knowledge in assessing the health of the spine.

In Sengupta et al.'s [28] work from 2024, Sengupta and colleagues made the following observation: This study provides a portable stethoscope that is based on a resonant microphone array. Through the use of wireless data transfers, the device makes it possible to monitor the noises of the lungs in real time. The stethoscope, which is equipped with microelectromechanical systems (MEMS) technology, is intended to enhance the capabilities of both patient care and diagnostics.

The authors of this research, Esfahani et al. [29], analyze the ways in which virtual reality (VR) might be beneficial to construction workers in order to improve their ability to respond to warnings that are sent by wearable sensing devices (WSDs). Increasing worker safety behavior via the use of virtual reality (VR) simulations for the purpose of teaching and training is the main objective of the project, which aims to reduce the number of accidents, illnesses, and injuries that are associated with construction.

Rodriguez and Wang examine the ways in which CRISPR-based approaches are being used to investigate the targets and mechanisms of action of medications via the use of precise gene editing in their study that was published in 2024 [30]. The research provides an explanation of the many CRISPR techniques, including CRISPR/Cas9, CRISPRi, and CRISPRa, that are used in the process of constructing disease models and identifying prospective therapy targets.

Following on from the previous section, inaccurate information can lead to heart failure, low blood pressure and headaches in patients for drug analysis are considered to be of paramount importance, such as Dijkshoorn et al. [17], Liu et al. [20] and Isola et al. [22]. Further, this research discusses the wearable body sensor network-enabled artificial neural network (WBSN-ANN), which helps predict performance, recall, precision, efficiency, and accuracy analyses.

3. Proposed method

In order to monitor a wide range of physiological factors, the bio-mechanical landscape (BML) technique makes use of sensors that are attached to the body. These sensors are able to collect data on bio-impedance, heart rate, blood pressure, and accelerations of the body. A comprehensive picture of a person's health may be obtained via the use of the BML technique, which incorporates data from a variety of information sources. An example of a key application is the employment of wireless body sensor networks (WBSNs), which allow remote monitoring via the use of autonomous sensors that are worn by persons. These networks make it possible to do accurate and simultaneous monitoring, which is especially beneficial for the elderly and others who suffer from chronic ailments. The implementation of machine learning techniques is very important in the field of medicine, and it is also critical to the components of WBSN-ANN, which include data gathering, fusion, risk assessment, and decision-making.

Based on evidence-based recommendations, every negative occurrence that a patient experiences while undergoing or perceived to be undergoing drug treatment and that actually or potentially hinders the therapy's intended aims was classified as

a drug therapy concern. In this healthcare monitoring system, the patient is constantly within range of the gateway that connects their WBAN devices to the medical central unit, even while on the go. These gadgets interact with a central medical unit at a clinic or hospital that monitors patients' vitals online. The elements of cardiovascular disease through drug analysis for patient elements are discussed below.

3.1. Section

Figure 1 illustrates:

Input: Wearable sensors attached to the body collect data in real time, which is then used to predict heart disease, temperature, and blood glucose levels before and after a meal. Data is transmitted and received through wireless networks and stored in the cloud. The suggested framework elucidates heart disease prediction. A patient's vitals, including their heart rate, breathing rate, and haemoglobin range, are monitored by sensors implanted in their body to identify illness.

Processing: The alerting system notifies the appropriate doctor and career using the adaptive alarming system. Notifications are sent out once the calculated value above the predetermined threshold is derived from earlier research and government conclusions. The system closely monitors things since the threshold model has varied values for different age groups. The wearable gadget continually uploads medical data from patients' bodies via several sensors. The monitoring system alerts the doctor and career when the measured value exceeds the predetermined threshold.

Output: The level of health risk determines the specific sensor data transmission requirements for each patient. A patient's health is more in danger if they have a history of heart attacks or other severe cardiovascular diseases—performance analysis as an output.



Figure 1. Cardiovascular disease through drug analysis.

3.2. Section

The structural elements of cardiovascular disease through drug analysis are shown in **Figure 1**. Further, the block structure of the biomechanics in drug analysis is discussed in **Figure 2**, and the patient factors during the drug analysis have been discussed as follows.



Figure 2. Block structure of biomechanics in drug analysis.

Figure 2 illustrates:

Input: A clinical chemist used in cardiovascular disease failure admitted who fulfilled the inclusion criteria a structured and pilot-tested questionnaire to gather data. Data sources included patient medical records (including case notes, heart failure, low blood pressure and headaches), interviews with patients and their careers, daily ward rounds and multidisciplinary meetings where each patient's diagnosis, treatment, and follow-up were discussed.

Processing: Sociodemographic, social drug use, medication adherence before admission, medical history, allergy history, and other pertinent information was gathered via interviews with patients and careers medication side effects, as well as natural remedies and over-the-counter the medicine cabinet in collection and analysis of patients' specific data. Medication evaluations took into account all of the patient's medications, including those prescribed, in addition to the following: the drug-safety profile, dose, frequency, length of therapy, reasons for drug usage, likelihood of under-treatment, therapeutic or pharmacological duplication, and possible drug-drug/disease interactions. The most well-recognized clinical and pharmaceutical risk factors for drug treatment complications were also documented. An internist and two clinical chemists reviewed the patients' records to ensure they were all prescribed the proper prescriptions, utilized the safest, most effective agent available, and were willing to take their medication as prescribed.

Output: A clinical pharmacist, a cardiologist, residents, medical interns, and nurses—any adverse event that involves. At the interdisciplinary conference, the issues were addressed or discussed. Drug therapy complications, possible side effects, and pharmacological remedies, which include suggestions to alter medication treatment (e.g., lower dosages or switch pharmaceuticals).

3.3. Section

Therefore, factors that mainly influence the learning vector quantization architecture for cardiovascular classifications have been discussed as follows:

Figure 3 illustrates the learning vector quantization network (LVQ), an example of a supervised learning network based on competition. Each transfer function represents a group in this system; therefore, it's possible to describe it as organizing patterns into groups. The system will have a set of learning patterns, acknowledged classifications, and an initial allocation of the output variable since it utilizes a learning algorithm. After training, LVQ would join the output channel and any input vectors into a single class. Clearly, "n" units are used as inputs and "m" units are used as outputs. All of the layers are fastened together and supported by weights. When training LVQ for cardiovascular classification, the following parameters were utilized.



Figure 3. Learning vector quantization architecture for cardiovascular classifications.

WBSN-ANN

From the above discussion on the drug analysis, cardiovascular diseases such as Dijkshoorn et al. [17], Liu et al. [20] and Isola et al. [22] need to improve several aspects. Therefore, this advent in the pathway for WBSN-ANN, which helps to predict the cardiovascular disease issues as influenced by heart failure, low blood pressure and headache: cardiovascular disease of input with the patient's data and health record are discussed below:

Figure 4 illustrates the WBSN-ANN cardiovascular disease prediction system framework through drug analysis.

The WBSN-ANN architecture unites wearable electronics with predictive analytics, empowering both patients and healthcare providers with more agency over their own personal health data. Here is what the approach includes: One technique that finds widespread use in the study and detection of drugs is chemiluminescence. There are conditions when it relies on the linear relationship between chemical luminescence intensity and chemical concentration as observed in a chemical detection system. To better understand pharmacological compounds, metabolites, and drug interactions, chemiluminescence is used. When looking for information on pharmacokinetics and pharmacodynamics, this research is the great resource.

Input: Drug analysis in cardiovascular care is still on the rise. It is difficult to find the most effective ANN works with datasets related to cardiovascular illness, even if there are many of them. The primary objective of the proposed work is to provide a machine learning-based cardiovascular disease prediction system that is very accurate. Coronary disease prediction system (CDPS) architecture is shown in **Figure 4**. The framework takes health record data as input and uses it to make

accurate predictions for expert advice. Choose the top WBSN method for handling instances of cardiovascular illness depending on how well the chosen classification algorithm performs.



Figure 4. Framework of the WBSN-ANN cardiovascular disease prediction system through drug analysis.

There are a lot of missing and noisy values in the actual world's data; hence, the first step in data mining is data preprocessing. To avoid these issues and create reliable predictions, the data is preprocessed. The raw data is inadequate and inconsistent. If any values are missing, they may be either eliminated or replaced with the average. Therefore, the collected data has to be slightly adjusted using a filtering strategy to conduct a practical analysis. Cut down on the amount of input characteristics before doing the data analysis. Having a large number of qualities adds complexity and decreases performance.

Post-processing: Not all attributes contribute equally to the effectiveness of predictions. The system's performance must not be compromised throughout the meticulous feature extraction process. The focus on therapeutic mechanisms improves the accuracy of drug discovery, similar to how mechanism-based diagnosis and therapy have affected clinical practice. More indications will be treatable, and clinical treatment will be more precise if drugs are matched to molecular pathways.

Output: There hasn't been enough financial incentive to get medicine from the idea to bedside for uncommon cardiovascular diseases, but the mechanical emphasis should help change that. This was characterized as a medication being given too quickly, an insufficient dosage frequency, an excessively lengthy term of drug treatment, a drug interaction leading to toxicity, or an inadequate dosage. Any untoward occurrence that a patient encounters during or perceived to be associated with drug treatment, which actually or potentially impedes the attainment of therapeutic objectives and which needs expert discretion to rectify, is considered a drug therapy issue.

$$\text{InfoNet}_j = \sum_{j}^{n} x_i \times W_{i,j} + b_j \tag{1}$$

where, x_i, $W_{i,j}$, b_j represent the input data, the weight between nodes, and the bias, respectively, in Equation (1).

$$f\left(\text{InfoNet}_j\right) = \max\left(0, \text{InfoNet}_j\right) \tag{2}$$

Next, the output nodes get the transformed data, which are used to forecast the occurrence of heart disease in Equation (2). Two nodes make up the output layer, which shows the outcomes of the binary classification (whether cardiac disease is present or not). The disease training process used starting weights for each input value. Afterwards, the backpropagation technique minimizes the actual and predicted output error. Equation (3) adjusts the weights throughout the deep learning model training process.

$$\Delta W_{i,j} = -\theta \frac{\delta E}{\delta W_{i,j}} \tag{3}$$

where θ represents the learning rate, called the positive constant, and E denotes the error; the challenging characteristic of such a cardiovascular disease using drug analysis is that heart failure, low blood pressure and headaches are ratified by using Equations (1)–(3) which is defined by Equation (4).

$$E_n = \frac{1}{2}\sum\nolimits_{p=1}^{n}\sum\nolimits_{o=1}^{m}(T_{io} - Y_{io})^2 \tag{4}$$

where p, o, T and Y stand for the sample size, output count, target output, and actual output, in that order. The training error updates all the weights and reevaluates the output layer's anticipated values. The procedure is repeated once the network achieves the minimum error between the actual and anticipated output. To train the ANN model suggested here, the authors utilized the Adam optimizer with a learning rate 0.03. In the Algorithm 1, we see the ensemble deep learning model's pseudocode.

Algorithm 1 Ensemble ANN-based cardiovascular disease prediction

1: Input: Number of features $X = x^1, x^2, \ldots, x^i$ for cardiovascular disease prediction
2: Output: The presence of cardiovascular disease or the absence of cardiovascular disease
3: Begin:
4: For number of training iterations do
5: Calculate the weighted sum and add bias in each
6: Hidden layer node by $\sum_i^n x_i \times W_{i,j} + b_j$.
7: $\left|\text{Compute } \Delta W_{i,j} = -\theta \frac{\delta E}{\delta W_{i,j}}\right|$ and
8: $E_n = \frac{1}{2}\sum_{p=1}^{n}\sum_{o=1}^{m}(T_{io} - Y_{io})^2$
9: |Choose α and update $W_{i,j}$.
10: |Repeat until error become minimal between T and Y
11: End for
12: Apply leaky ReLU activation function
13: $f\left(\text{InfoNet}_j\right) = \max\left(0, \text{InfoNet}_j\right)$ to predict cardiovascular disease for drug analysis
14: // To achieve high accuracy.
15: Use LogitBoost as a meta-learning classifier.

Equation (5) illustrates the c and $W_{i,f_i} \in R^+$ denotes the class variable value

and the particular weight of the feature value f_i for class c, respectively. The value is related to the feature value. f_i, where a different weight is assigned to each feature value. The range of W_{i,f_i} is from zero to 1, which denotes the importance of the feature value f_i for the heart disease prediction task.

$$W_{i,f_i} = \sum_{c} P(c|f_i)\log\frac{P(C|f_i)}{P(C)} \tag{5}$$

$$(X) = \sum_{i=1}^{L}(Bi\ hi\ (X)) \tag{6}$$

$$\arg\min c \sum_{i=1}^{n}\sum_{j=1}^{c}(wijm||Xi - cj||2) \tag{7}$$

Combine Equations (6) and (7) to get Equation (8) for disease identification.

$$f(X) = \arg\min c \sum_{i=1}^{n}\sum_{j=1}^{c}(wijm||Xi - cj||2)\sum_{i=1}^{L}(Bi\ hi\ (X)) \tag{8}$$

Equations (6)–(8) illustrate,

c: Centroid value of features.

$f(X)$: Features of the datasets.

wij : Unknown knowledge.

Xi: Individual feature of the dataset.

L: Hidden nodes.

Bi: Resultant expected output.

hi: Individual hidden node.

n: Nodes.

$$\overline{X^{CT}}j = \frac{1}{n}\sum X_i^{CT_j} \tag{9}$$

where X, CT_j, i, $X_i^{CT_j}$, $\overline{X^{CT}}j$ represent features such that X = {"age", "chol", "sex", "heart rate", …, "CAD history", "smoking history"}, a category level such that $CT_j = \{0,1,2\}$, the pattern number ith pattern of feature X under the CT_j category, and the mean of feature X under the category CT_j.

The heart disease D^{hd} dataset contains several features, and every feature includes different numerical values, increasing difficulties during the computation process. Therefore, a normalization technique is used to normalize the dataset D^{hd} in the range between zero and 1. This method plots a numerical value, DV, of the original dataset D^{hd} into DV_{norm} within the interval [0, 1] by using the following Equation (10):

$$DV_{\text{norm}} = \frac{D^{hd} - DV_{\min}}{DV_{\max} - DV_{\min}} \times [new_{\max} - new_{\min}] + new_{\min} \tag{10}$$

Here, DV_{norm} , D^{hd} , $DV_{\min}$ and $DV_{\max}$ are the normalized data value, the original data value, the minimum data value, and the maximum data value, respectively, in the entire dataset, while $new_{\max}$ and $new_{\min}$ indicate the range of the converted dataset. We use $new_{\max} = 1$ and $new_{\min} = 0$ from Equation (10) calculates the performance analysis.

The activation functions of WBSN-ANN, when it comes to detecting problems,

are similar to a set of transfer functions given cardiovascular disease in drug analysis. Input and feedback are considered to properly ascertain the necessary output for cardiovascular disease prediction for drug analysis.

In the realm of machine learning, a technique known as LVQ has shown positively promising outcomes.

Primary data refers to information that has been obtained from sources such as sensors or eyewitness testimonies without any editing. With regard to the prognosis of cardiovascular disease, physiological measures, which include an electrocardiogram (ECG), blood pressure, and heart rate, are regarded to be the most important data. These data are used as input qualities by the algorithm that makes predictions. Data that has been converted, characteristics extracted from, or somehow generated from the original data is referred to as secondary data. Engineered features, feature vectors, and statistical summaries are all examples of what are included in this category which is derived from primary data. Model performance may be improved by the collection of relevant information through the use of secondary data.

There are several hardware requirements that the primary data-generating sensor has to fulfil, including the following:

- Accuracy: Accurate measurements are essential to the creation of reliable predictions.
- In the event that the sample rate is sufficiently high, it is possible to record the essential and rapid physiological changes.
- The capacity to connect with medical monitoring systems or wearable technology is referred to as interoperability.
- Noise reduction is a powerful tool that may be used to combat artifacts and noise.
- For the purpose of evaluating the effectiveness of LVQ, it could be useful to compare it to other algorithms.

Further it has been compared with several algorithms which is listed here:

- A model of a neural network that makes use of radial activation functions is referred to as an RBF.
- The support vector machine (SVM) is a technology that may be used rather well for binary classification.
- Random Forests, which represents an ensemble of decision trees.
- Using k-nearest neighbors (K-NN), which is a linear model for binary classification, instance-based learning is carried out.
- Logistic regression is a helpful tool for binary classification.

LVQ is a useful resource for disease prediction in cardiovascular disease. Through the use of primary data, secondary features, and the appropriate technology, we are able to enhance the results for patients and initiate early intervention.

4. Result and discussion

The research concludes that the WBSN-ANN accurately foretells and verifies the optimized biomechanics for cardiovascular disease through analysis based on precision, accuracy rate, recall, specificity, and performance analysis, which are

discussed as follows.

Dataset description: For this particular result and discussion, 166 audit risk assessment data worldwide have taken 10 patients' data [31]. Diseases are burdensome because they kill individuals and inflict misery on those who live with them; nevertheless, focusing on mortality ignores this fact. A more complete picture of health outcomes may be obtained by measuring mortality and morbidity, the two most common illnesses. The wearable body sensor network-enabled artificial neural network (WBSN-ANN) technique has gained popularity as a result of the fact that it has the potential to be used in real-world clinical applications, such as continuous monitoring and personalized healthcare. An extended investigation of this method reveals a number of significant aspects, including the following:

- WBSN-ANN makes it possible to gather data in a continuous manner, which enables monitoring to continue for extended periods of time. This allows for the optimization of efficiency over time.
- It is possible to measure its efficacy by monitoring the outcomes of patients, the progression of their illnesses, and their responses to therapy over a long period of time, which may range from months to even years.
- Trustworthiness: The reliability of WBSN-ANN is dependent on the accuracy of the sensors, the speed with which they communicate data, and the durability of the sensors themselves.
- Data collected from the actual world has shown that it is effective in a variety of settings, such as when the patient is moving, when the environment is changing, and when wearable sensors are functioning.
- There are still significant problems that need to be fixed, such as incorrectly aligned data, drift in sensors, and restricted battery life.
- There are significant challenges involved in continuously lowering the number of false alarms and increasing patient compliance.

They can focus on the study findings report's section that discusses relevant data to reflect the quality of the findings:

$$\text{Precision} = \frac{\text{TruePos}}{(\text{TruePos} + \text{FalsePos})} \tag{11}$$

Equation (11), showing the percentage of big positive data as among true positive assessed by precision, can be calculated in **Table 1**.

$$\begin{aligned} \text{Accuracyrate} &= \frac{(\text{TruePos} + \text{FalsePos})}{(\text{True} + \text{False})} \\ &= \frac{(\text{TruePos} + \text{FalsePos})}{(\text{TruePos} + \text{FalsePos} + \text{TrueNeg} + \text{FalseNeg})} \end{aligned} \tag{12}$$

Equation (12) shows the accuracy rate in evaluating the whole sample and positive and negative outcomes in **Table 2**.

$$\text{Recall} = \frac{\text{TruePos}}{(\text{TruePos} + \text{FalseNeg})} = \frac{1 - \text{FalseNeg}}{\text{Total}} \tag{13}$$

Equation (13) displays the recall % of adequately identified positive instances to the total number of positive cases calculated.

Equation (14) negative rate is another name for the false-positive rate for specificity, which can be calculated in **Figure 5**.

The formula is

$$\text{Specificity} = \frac{\text{TruePos}}{(\text{TruePos} + \text{FalseNeg})} = \frac{1 - \text{FalsePos}}{\text{Total}} \tag{14}$$



Figure 5. Specificity analysis for cardiovascular disease.

Figure 5 illustrates the specificity analysis for cardiovascular disease for a health monitoring system that gathers data from patients' sensors, makes intelligent predictions about their health, and communicates with clinicians via their Android-powered mobile devices. By using their mobile devices, patients can take an active role in their healthcare, and doctors will have 24/7 access to their medical records, giving patients feedback on their medical condition via the cloud. With cloud computing devices, the suggested system may collect sufficient data about the patient's illness and send it to an off-site location. While it's true that mobile devices offer great potential as tools for patients to track and manage their health, there are some limits to how much processing power or data they can handle. Compared to other approaches, HPLC-RI, PCa, and HIV, the proposed WBSN-ANN is a cardiovascular disease for specificity analysis and can be calculated using Equation (14). The suggested approach outperforms the current strategy by a specificity analysis of 97.2% and 95.4%.

These metrics assess how well a classifier can classify data in different situations. If exactness is considered, no training is required; however, evaluating a model's performance based on accuracy is flawed when there is a great deal of variance within the data categories. The samples that were analyzed all belong to the vast number category. This does not reflect the model's capabilities since the dependability is superb.

Table 1 illustrates precision analysis for heart failure; this phrase is frequently used to describe computational simulations of individuals and disease processes. By searching the electronic health record for appropriate cohorts of patients with the condition of interest, both those who are "treated" and those who are "controls," we may find out whether the new drug-disease combination works. The inherently retrospective nature of these trials, the potential confounding effect of multiple diseases in a single patient, and the technical difficulties inherent to data mining are some of the evident limitations. Compared to other approaches, HPLC-RI, PCa, and HIV, the proposed WBSN-ANN is a cardiovascular disease for precision analysis and can be calculated using Equation (11). The suggested approach outperforms the

current strategy by a precision analysis of 71.6%.

Table 1. Precision analysis for heart failure.

No. of patients	HPLC-RI	PCa	HIV	WBSN-ANN
1	20.6	37.8	61.1	53.2
2	26.4	23.1	36.4	51.6
3	23.1	31.6	29.1	42.1
4	18.3	41.7	26.2	49.2
5	39.7	19.6	34.6	39.7
6	21.2	18.2	35.3	27.9
7	38.1	21.1	46.1	64.5
8	30.9	40.3	42.5	56.4
9	31.2	56.4	28.6	62.8
10	42.8	41.3	51.9	71.6

Table 2 illustrates the accuracy analysis for low blood pressure inherent challenges of generalizability in electronic case. This second point is critical to consider when designing trials with run-in phases; these periods exclude individuals who aren't good drug adherents or who have intolerances, which can lead to results that are skewed towards a favourable drug impact rather than what would be possible with regular treatment. In addition, there is a possibility for positive and negative bias in results due to disparities between real-life care and care given to trial participants, which might affect medication repurposing. Compared to other approaches, HPLC-RI, PCa, and HIV, the proposed WBSN-ANN is a cardiovascular disease for accuracy analysis and can be calculated using Equation (12). The suggested approach outperforms the current strategy by an accuracy analysis of 63.7%.

Table 2. Accuracy analysis for low blood pressure.

No. of patients	HPLC-RI	PCa	HIV	WBSN-ANN
1	39.7	31.1	52.1	58.4
2	29.6	36.2	29.5	56.8
3	18.7	32.6	42.1	31.9
4	31.8	21.6	48.6	52.4
5	16.4	28.7	34.6	61.2
6	30.7	48.3	34.6	53.1
7	19.3	49.6	52.7	63.4
8	40.2	41.6	31.6	61.9
9	24.5	52.3	61.9	62.3
10	29.3	49.6	56.4	63.7

Figure 6 illustrates recall analysis for headaches through wearable sensors attached to the body, which collect data in real time and are transmitted and received through wireless networks and stored in the cloud. The suggested framework

elucidates heart disease prediction. Heart rate, respiration rate, and haemoglobin range sensors are used for prediction purposes; these sensors are connected to the patient's body to identify illness. The alarm system employs an adaptive alarm method to notify the appropriate doctor and carer. Compared to other approaches, HPLC-RI, PCa, and HIV, the proposed WBSN-ANN is a cardiovascular disease for recall analysis and can be calculated using Equation (13). The suggested approach outperforms the current strategy by a precision analysis of 86.8% and 89.2%.



Figure 6. Recall analysis for headache.



Figure 7. Performance analysis for WBSN-ANN.

Figure 7 illustrates the performance analysis for WBSN-ANN, where the system determines the patient's gender. The fundamental rationale for this is that cardiac patients of male and female genders need distinct recommendations. Furthermore, the method determines the patient's age and assigns it to one of three categories: juvenile, adult, or elderly. Afterwards, the model suggested a food and exercise regimen tailored to the patient's age, gender, and anticipated outcomes (such as quitting smoking, ramping up physical activity, maintaining a healthy weight, and cutting down on meat). Furthermore, if the expected result is unfavourable and the value of the extracted characteristics is too high, this module will contact rescue units and emergency services. Compared to other approaches, HPLC-RI, PCa, and HIV, the proposed WBSN-ANN is a cardiovascular disease for

performance analysis and can be calculated using Equation (10). The suggested approach outperforms the current strategy by a performance analysis of 89.4% and 94.2%.

Table 3. Comparison summary for drug analysis.

Metrics	WMCGP	ATLAS	SEM	BPNN-ML
Precision analysis (%)	42.8	41.3	51.9	71.6
Accuracy analysis (%)	29.3	49.6	56.4	63.7
Recall analysis (%)	32.3 41.9	53.3 62.2	65.3 55.4	86.8 89.2
Sensitivity analysis (%)	61.2 51.9	53.8 78.7	91.3 86.4	97.2 95.4
Performance analysis (%)	50.2 42.2	68.2 62.2	72.5 85.6	89.4 94.2

The proposed BPNN-ML improves the predicted precision analysis 71.6%, accuracy analysis 63.7%, recall analysis 86.8%, 89.2%, Sensitivity analysis 97.2%, 95.4% and performance analysis 89.4%, 94.2%, respectively (**Table 3**).

Therefore, future work discusses cardiovascular disease for drug analysis with WBSN-ANN assistance to validate the performance analysis, recall analysis, precision analysis, efficiency analysis and accuracy analysis results.

Limitation and challenges:

- Both clinical safety and translation continue to face a significant obstacle in the form of the development of drug delivery systems that are both safe and effective.
- Because of the stringent safety requirements and the bureaucratic red tape, it is difficult to incorporate effective experimental ideas in the clinical practice that is regularly performed.
- Despite the progress that has been made in understanding the molecular mechanisms that are responsible for atherosclerotic plaques, new medicine delivery techniques are still necessary.
- Developing novel approaches is necessary in order to target ischemic myocardium, vulnerable plaques, and other areas that are affected.
- There should be individualized treatment regimens for cardiovascular disease that are executed for each individual patient.
- The use of tailored medicine delivery systems has the potential to increase both the efficacy and safety of treatment approaches.
- In light of these challenges, it is essential to maintain research efforts and collaborate with other organizations in order to improve the drug therapies for cardiovascular diseases.

5. Conclusion

HPLC-RI, PCa, and HIV are similar to cardiovascular disease for drug analysis characteristics, although their efficacy is not anticipated; they use WBSN-ANN approaches, the benefits are anticipated accurately, and the trial results are convincing. As part of this research project, a WBSN-ANN will be built to address

the increasing need to optimize cardiovascular disease for drug analysis. To improve prediction accuracy, this novel framework finds the optimal Collection of characteristics and calculates their unique relevance in the datasets. In addition, it can analyze the heart patient's health and suggest a diet or exercise program automatically. WBSN-ANN effectively extracts useful characteristics from structured and unstructured data and represents them with low-dimensional and particular weights to enhance heart disease prediction. Feature fusion, attribute selection, feature weighting, and disease-risk prediction algorithms may be linked to it. Data mining will enhance heart disease detection datasets and feature fusion in future research. Furthermore, new approaches will be developed for feature reduction to manage massive amounts of healthcare information and features. Lastly, we will look at a more advanced approach to handling missing values and noise and deleting unimportant features to get efficient outcomes.

Ethical approval: Not applicable.

Conflict of interest: The author declares no conflict of interest.

References

1. Ma X, Fernández FM. Triboelectric nanogenerator-coated blade spray mass spectrometry for volume-limited drug analysis. International Journal of Mass Spectrometry. 2024; 495: 117164. doi: 10.1016/j.ijms.2023.117164
2. Jain B, Jain R, Kabir A, et al. Exploiting the potential of fabric phase sorptive extraction for forensic food safety: Analysis of food samples in cases of drug facilitated crimes. Food Chemistry. 2024; 432: 137191. doi: 10.1016/j.foodchem.2023.137191
3. Özbek O, Berkel C, Isildak Ö. Applications of Potentiometric Sensors for the Determination of Drug Molecules in Biological Samples. Critical Reviews in Analytical Chemistry. 2020; 52(4): 768-779. doi: 10.1080/10408347.2020.182506
4. Figtree GA, Broadfoot K, Casadei B, et al. A call to action for new global approaches to cardiovascular disease drug solutions. European Heart Journal. 2021; 42(15): 1464-1475. doi: 10.1093/eurheartj/ehab068
5. Sethi Y, Patel N, Kaka N, et al. Precision Medicine and the future of Cardiovascular Diseases: A Clinically Oriented Comprehensive Review. Journal of Clinical Medicine. 2023; 12(5): 1799. doi: 10.3390/jcm12051799
6. Jairoun AA, Al-Himyari SS, Shahwan M, et al. Community pharmacists' perspectives on cardiovascular disease pharmaceutical care in the United Arab Emirates: a questionnaire survey-based analysis. Frontiers in Pharmacology. 2023; 14. doi: 10.3389/fphar.2023.1237717
7. Wang Q, Wang Z, Chen M, et al. Causality of particulate matter on cardiovascular diseases and cardiovascular biomarkers. Frontiers in Public Health. 2023; 11. doi: 10.3389/fpubh.2023.1201479
8. Fang X, Ardehali H, Min J, et al. The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease. Nature Reviews Cardiology. 2022; 20(1): 7-23. doi: 10.1038/s41569-022-00735-4
9. Chen X, Cai Q, Liang R, et al. Copper homeostasis and copper-induced cell death in the pathogenesis of cardiovascular disease and therapeutic strategies. Cell Death & Disease. 2023; 14(2). doi: 10.1038/s41419-023-05639-w
10. Canoy D, Nazarzadeh M, Copland E, et al. How Much Lowering of Blood Pressure Is Required to Prevent Cardiovascular Disease in Patients with and Without Previous Cardiovascular Disease? Current Cardiology Reports. 2022; 24(7): 851-860. doi: 10.1007/s11886-022-01706-4
11. Schneider ZD, Shah MP, Boily MC, et al. Mass Drug Administration to Reduce Malaria Transmission: A Systematic Review and Meta-Analysis. The American Journal of Tropical Medicine and Hygiene. 2024; 110(4_Suppl): 17-29. doi: 10.4269/ajtmh.22-0766
12. O'Sullivan JW, Raghavan S, Marquez-Luna C, et al. Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement from the American Heart Association. Circulation. 2022; 146(8). doi: 10.1161/cir.0000000000001077
13. Zhang L, Bao Y, Tao S, et al. The association between cardiovascular drugs and depression/anxiety in patients with cardiovascular disease: A meta-analysis. Pharmacological Research. 2022; 175: 106024. doi: 10.1016/j.phrs.2021.106024
14. Samson R, Ennezat PV, Le Jemtel TH, et al. Cardiovascular Disease Risk Reduction and Body Mass Index. Current

Hypertension Reports. 2022; 24(11): 535-546. doi: 10.1007/s11906-022-01213-5
15. Tao LC, Xu JN, Wang T ting, et al. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovascular Diabetology. 2022; 21(1). doi: 10.1186/s12933-022-01511-x
16. Al-Sanea MM, Gamal M. Critical analytical review: Rare and recent applications of refractive index detector in HPLC chromatographic drug analysis. Microchemical Journal. 2022; 178: 107339. doi: 10.1016/j.microc.2022.107339
17. Dijkshoorn B, Raadsen R, Nurmohamed MT. Cardiovascular Disease Risk in Rheumatoid Arthritis Anno 2022. Journal of Clinical Medicine. 2022; 11(10): 2704. doi: 10.3390/jcm11102704
18. Terentes-Printzios D, Ioakeimidis N, Rokkas K, et al. Interactions between erectile dysfunction, cardiovascular disease and cardiovascular drugs. Nature Reviews Cardiology. 2021; 19(1): 59-74. doi: 10.1038/s41569-021-00593-6
19. Zhu W, Wu J, Huang J, et al. Multi-omics analysis reveals a macrophage-related marker gene signature for prognostic prediction, immune landscape, genomic heterogeneity, and drug choices in prostate cancer. Frontiers in Immunology. 2023; 14. doi: 10.3389/fimmu.2023.1122670
20. Liu B, Cai G, Qian J, et al. Machine Learning Model Training and Practice: A Study on Constructing a Novel Drug Detection System. International Journal of Computer Science and Information Technology. 2023; 1(1): 139-146. doi: 10.62051/ijcsit.v1n1.19
21. Grinspoon SK, Fitch KV, Zanni MV, et al. Pitavastatin to Prevent Cardiovascular Disease in HIV Infection. New England Journal of Medicine. 2023; 389(8): 687-699. doi: 10.1056/nejmoa2304146
22. Isola G, Santonocito S, Distefano A, et al. Impact of periodontitis on gingival crevicular fluid miRNAs profiles associated with cardiovascular disease risk. Journal of Periodontal Research. 2022; 58(1): 165-174. doi: 10.1111/jre.13078
23. Smith J, Nguyen P. Advanced spectroscopic techniques for drug analysis in biomechanical systems. Journal of Biomedical Spectroscopy. 2024; 14(1): 45-59.
24. Patel R, Li W. Microfluidic platforms for high-throughput drug screening. Lab on a Chip. 2024; 22(2): 123-139.
25. Brown T, Zhao L. Computational modeling in drug discovery: Integrating AI and machine learning. Computational Biology and Chemistry. 2024; 28(3): 205-219.
26. Martinez F, Kim S. Nanotechnology in drug delivery systems: Current trends and future directions. Nanomedicine. 2024; 19(4): 320-335.
27. Abbasi-Ghiri A, Ebrahimkhani M, Arjmand N. Novel force–displacement control passive finite element models of the spine to simulate intact and pathological conditions; comparisons with traditional passive and detailed musculoskeletal models. Journal of Biomechanics. 2022; 141: 111173. doi: 10.1016/j.jbiomech.2022.111173
28. Sengupta A, Roy A, Gao H, et al. Wearable Stethoscope Based on Resonant Microphone Array with Wireless Data Transfer. In: Proceedings of the 2024 IEEE 37th International Conference on Micro Electro Mechanical Systems (MEMS). pp. 101-104.
29. Esfahani MT, Awolusi I, Nnaji C. Using Virtual Reality to Enhance Construction Workers' Response to Alerts from Wearable Sensing Devices: A Review. In: Proceedings of the Construction Research Congress 2024. pp. 1278-1287.
30. Rodriguez M, Wang Y. CRISPR-based tools for drug discovery and development. Genome Editing. 204; 6(1): 98-113.
31. Available online: https://www.kaggle.com/datasets/iamsouravbanerjee/cause-of-deaths-around-the-world (accessed on 18 March 2024).